Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Ocuphire Pharma, Inc. | ex32_2.htm |
| EX-32.1 - EXHIBIT 32.1 - Ocuphire Pharma, Inc. | ex32_1.htm |
| EX-31.2 - EXHIBIT 31.2 - Ocuphire Pharma, Inc. | ex31_2.htm |
| EX-31.1 - EXHIBIT 31.1 - Ocuphire Pharma, Inc. | ex31_1.htm |
| EX-24.1 - EXHIBIT 24.1 - Ocuphire Pharma, Inc. | ex24_1.htm |
| EX-12.1 - EXHIBIT 12.1 - Ocuphire Pharma, Inc. | ex12_1.htm |
| EX-10.8 - EXHIBIT 10.8 - Ocuphire Pharma, Inc. | ex10_8.htm |
| 10-K - 10-K - Ocuphire Pharma, Inc. | form10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-218285) and Form S-8 (File No. 333-189240, 333-129294 and 333-217627) of Rexahn Pharmaceuticals, Inc., of our report dated March 9, 2018, relating to the financial statements and the effectiveness of Rexahn Pharmaceuticals, Inc.'s internal control over financial reporting, which appear in this Annual Report on Form 10- K for the year ended December 31, 2017.
|
/s/ BAKER TILLY VIRCHOW KRAUSE, LLP
|
|
Wyomissing, Pennsylvania
|
|
March 9, 2018
|